Overview of Recent Transaction by FMR LLC (Trades, Portfolio) On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 3,605,932 shares in Fulerum Therapeutics Inc (FULC, Financial), a clinical-stage biopharmaceutical company. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company to 1,724,014 shares, marking a notable shift in its investment strategy. The shares were traded at a price of $3.57, reflecting the firm's adjustment in its portf ...

A downtrend has been apparent in Fulcrum Therapeutics, Inc. (FULC) lately with too much selling pressure. The stock has declined 57.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical in ...

Fulcrum Therapeutics, Inc. (FULC) has been beaten down lately with too much selling pressure. While the stock has lost 65.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum ...

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FULC. Investigation Details On September 12, 2024, Fulcrum announced that "its Phase 3 REACH trial evaluating losma ...

Shares of Fulcrum Therapeutics, Inc. (FULC) plunged 61.1% on Sept. 12 after the company announced disappointing top-line data from the phase III REACH study, which evaluated its pipeline candidate, losmapimod, for treating patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disease. Currently, there are no treatments approved for the given indication. The study did not meet its primary endpoint as treatment with losmapimod failed to demonstrate a change from baseline in rela ...

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences: Wells Fargo Healthcare Conference Wednesday, September 4, 2024 Boston, MA Morgan Stanley 22nd Annual Global Healthcare Conference Frid ...

Fulcrum Therapeutics, Inc. (FULC) closed the last trading session at $9.42, gaining 6.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.11 indicates a 71% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $5.78. While the lowest estimate of $5 indicates a 46.9% decline from the current price level, the most optimistic anal ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Results Conference Call July 31, 2024 8:00 AM ET Company Participants Alex Sapir - CEO and President Alan Musso - CFO Iain Fraser - SVP of Early Development Conference Call Participants Corinne Johnson - Goldman Sachs Kristen Kluska - Cantor Fitzgerald Joseph Schwartz - Leerink Partners Dae Gon Ha - Stifel Gregory Renza - RBC Capital Markets Matthew Biegler - Oppenheimer Operator Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other juri ...

• Cash Position: As of June 30, 2024, cash, cash equivalents, and marketable securities were $273.8 million, as compared to $236.2 million as of December 31, 2023. The increase in our cash position is due to the $80.0 million upfront payment received from Sanofi in the second quarter of 2024, partially offset by cash used to fund our operating activities in 2024. • Collaboration Revenue: Collaboration revenue was $80.0 million for the three months ended June 30, 2024, as compared to $0.9 million for the thr ...